Publications

Data by Flouri et al. support greater drug persistence with secukinumab than with TNF inhibitors in patients with axSpA and peripheral spondyloarthritis, both with respect to efficacy- and safety-related discontinuations, while the achievement of 6-month treatment targets was comparable. Flouri et al. compared long term treatment persistence, efficacy and safety between secukinumab and TNF inhibitors in a cohort of patients with SpA treated in real life.

Mease et al. report that patients without radiographic progression through 2 years of secukinumab treatment had greater achievement of LDA states at Week 104 than patients with radiographic progression. This post hoc analysis by Mease et al. of the FUTURE 5 study evaluated the relationship between radiographic progression status at Week 104 and achievement of LDA or remission and identified demographics and clinical characteristics that were associated with radiographic progression status at Week 104.

Wang et al. validated the effectiveness and safety of UPA in this real-world study of Chinese PsA patients. UPA demonstrated comparable effectiveness to secukinumab (SEC) in psoriatic lesion improvement while showing comparable joint symptom relief compared with adalimumab (ADA), coupled with a favourable safety profile.

Heiting et al. investigated whether the initiation of IL-17 blockade with secukinumab improves bone turnover, bone mineral density, and microarchitecture in axSpA patients. Despite symptomatic benefits of therapy with secukinumab, with improvements in pain and function, there were few biochemical, densitometric, or microarchitectural changes in skeletal health over two years of treatment with secukinumab. Larger, longer-term controlled studies using sensitive metrics such as HR-pQCT to follow bone quality are needed to improve our understanding of bone health in axSpA and the relation to disease activity and therapy.

In more than 1500 patients from 13 European countries, Pons et al. demonstrated that secukinumab retention rates after four years were approximately 50% in both axSpA and PsA patients. Pons et al. aimed to assess retention rates and proportions of patients achieving remission and LDA, according to disease activity measures and patient-reported outcomes at 24 and 48 months, in axSpA and PsA patients initiating secukinumab. In this large real-world study, Pons et al., for the first time, report 48-month retention rates as well as rates of remission and LDA. Importantly, b/tsDMARD naïve patients demonstrated higher retention, remission and LDA rates than patients with prior b/tsDMARDs exposure, particularly in axSpA.  

Kaya et al. reported that switching to secukinumab or cycling to another TNFi after first TNFi failure in axSpA led to comparable drug survival, with predictive factors differing by treatment. The study reports that smoking and Achilles enthesitis were associated with higher SEC discontinuation, while high CRP and primary TNFi failure predicted TNFi discontinuation.